Kura Oncology, Inc.
AD/Director, Patient Advocacy
Kura Oncology, Inc., Boston, Massachusetts, us, 02298
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.We are seeking a dynamic and experienced Director of Patient Advocacy to join our team. In this pivotal role, you will be the key liaison between our organization and patient advocacy groups, external alliances,
Increase your chances of an interview by reading the following overview of this role before making an application.and professional medical associations within the oncology and hematology therapeutic areas. This critical role will help to define Kura’s patient advocacy priorities and oversee advocacy group collaborations that educate and activate patients to seek optimal care, break down barriers to patient access, and bring patient insights into the company.
Essential Job FunctionsDevelop and execute a comprehensive patient advocacy and patient engagement strategy tailored to the unique needs of our oncology and hematology portfolioLead the development of advocacy plans aligned with brand strategic imperatives and corporate strategy, focusing on disease awareness, access and reimbursement, post-market surveillance, adherence, and psychosocial support.Establish and implement best practices in patient advocacy, utilizing insights from the patient experience to inform strategies and initiatives.Champion a patient-centric approach across our portfolio, ensuring that the patient and caregiver perspective are integrated into all aspects of our work.Stay abreast of regulatory, legal, government affairs policy, and social media developments impacting patient advocacy and our therapeutic areas’.Educate internal teams on the importance and value of patient advocacy, particularly within specific disease areasGather feedback from patients, caregivers, healthcare professionals, policymakers, and other stakeholders to inform business decisions and enhance our support offerings.Provide strategic guidance on patient-directed campaigns, ensuring that they prioritize patient needs and align with our values of patient centricityJob RequirementsBachelor’s degree in relevant field, advanced degree preferred.Minimum of 7 years of experience in patient advocacy, preferably within the oncology or hematology space.Proven track record of developing and implementing successful patient engagement strategies. Must have the ability to effectively collaborate with, motivate and influence various levels within the organization, and forge strong relationships with stakeholders outside of the organization.Strong understanding of regulatory and policy landscape related to patient advocacy. Knowledge of marketing, strategic and long-range planning, training, and/or market accessExcellent communication and interpersonal skills, with the ability to collaborate effectively with internal and external stakeholders.Demonstrated ability to lead and inspire cross-functional teams.Passion for improving the lives of patients and caregivers affected by oncology and hematology conditions. Ability to travel up to 30% of the time; domestic and limited international.The base range for an Associate Director is $180,000 - $192,000 and for a Director, it is $221,000 - $233,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.Kura’s Values that are used for candidate selection and performance assessments:We work as one for patientsWe are goal-focused and deliver with excellenceWe are science-driven courageous innovatorsWe strive to bring out the best in each other and ourselvesThe Kura PackageCompetitive comp packageBonus401K + Employer contributionsGenerous stock optionsESPP Plan20 days of PTO to start18 Holidays (Including Summer & Winter Break)Generous Benefits Package with a variety of plans available with a substantial employer matchPaid Paternity/Maternity LeaveIn-Office Catered lunchesHome Office SetupLifestyle Spending StipendCommuter Stipend (Boston Office)Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website atwww.kuraoncology.com and follow us onX andLinkedIn .Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.Accepted file types: pdf, doc, docx, txt, rtfAccepted file types: pdf, doc, docx, txt, rtfWhat is your preferred name? *Where did you hear about this job? * Select...Are you open to considering relocation to Boston? Select...Are you open to considering relocation to San Diego? Select...Will you now or in the future require sponsorship for employment to work in the United States? * Select...Why are you the best candidate for the job?What are your salary expectations?Why do you want to work for Kura Oncology?Why are you looking for a new job?Describe the work environment or culture and its management style in which you have experienced the most success.If you were referred by a Kura employee, please share the name of who referred you.EducationSchool * Select...Degree * Select...Select...Select...Start date yearEnd date month Select...End date yearVoluntary Self-Identification For government reporting purposes, we ask candidates to respond to the below self-identification survey.Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file.As set forth in Kura Oncology’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law.If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows:A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.Select...Voluntary Self-Identification of Disability
Form CC-305Page 1 of 1OMB Control Number 1250-0005Expires 04/30/2026Voluntary Self-Identification of Disability Form CC-305 Page 1 of 1 OMB Control Number 1250-0005 Expires 04/30/2026Why are you being asked to complete this form?We are a federal contractor or subcontractor. The law requires us to provide equal employment opportunity to qualified people with disabilities. We have a goal of having at least 7% of our workers as people with disabilities. The law says we must measure our progress towards this goal. To do this, we must ask applicants and employees if they have a disability or have ever had one. People can become disabled, so we need to ask this question at least every five years.Completing this form is voluntary, and we hope that you will choose to do so. Your answer is confidential. No one who makes hiring decisions will see it. Your decision to complete the form and your answer will not harm you in any way. If you want to learn more about the law or this form, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp .How do you know if you have a disability?
A disability is a condition that substantially limits one or more of your “major life activities.” If you have or have ever had such a condition, you are a person with a disability.
Disabilities include, but are not limited to:Alcohol or other substance use disorder (not currently using drugs illegally)Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, HIV/AIDSBlind or low visionCancer (past or present)Cardiovascular or heart diseaseCeliac diseaseCerebral palsyDeaf or serious difficulty hearingDiabetesDisfigurement, for example, disfigurement caused by burns, wounds, accidents, or congenital disordersEpilepsy or other seizure disorderGastrointestinal disorders, for example, Crohn's Disease, irritable bowel syndromeIntellectual or developmental disabilityMental health conditions, for example, depression, bipolar disorder, anxiety disorder, schizophrenia, PTSDMissing limbs or partially missing limbsMobility impairment, benefiting from the use of a wheelchair, scooter, walker, leg brace(s) and/or other supportsNervous system condition, for example, migraine headaches, Parkinson’s disease, multiple sclerosis (MS)Neurodivergence, for example, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, dyslexia, dyspraxia, other learning disabilitiesPartial or complete paralysis (any cause)Pulmonary or respiratory conditions, for example, tuberculosis, asthma, emphysemaShort stature (dwarfism)Traumatic brain injuryDisability Status Select...
PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.
#J-18808-Ljbffr
Increase your chances of an interview by reading the following overview of this role before making an application.and professional medical associations within the oncology and hematology therapeutic areas. This critical role will help to define Kura’s patient advocacy priorities and oversee advocacy group collaborations that educate and activate patients to seek optimal care, break down barriers to patient access, and bring patient insights into the company.
Essential Job FunctionsDevelop and execute a comprehensive patient advocacy and patient engagement strategy tailored to the unique needs of our oncology and hematology portfolioLead the development of advocacy plans aligned with brand strategic imperatives and corporate strategy, focusing on disease awareness, access and reimbursement, post-market surveillance, adherence, and psychosocial support.Establish and implement best practices in patient advocacy, utilizing insights from the patient experience to inform strategies and initiatives.Champion a patient-centric approach across our portfolio, ensuring that the patient and caregiver perspective are integrated into all aspects of our work.Stay abreast of regulatory, legal, government affairs policy, and social media developments impacting patient advocacy and our therapeutic areas’.Educate internal teams on the importance and value of patient advocacy, particularly within specific disease areasGather feedback from patients, caregivers, healthcare professionals, policymakers, and other stakeholders to inform business decisions and enhance our support offerings.Provide strategic guidance on patient-directed campaigns, ensuring that they prioritize patient needs and align with our values of patient centricityJob RequirementsBachelor’s degree in relevant field, advanced degree preferred.Minimum of 7 years of experience in patient advocacy, preferably within the oncology or hematology space.Proven track record of developing and implementing successful patient engagement strategies. Must have the ability to effectively collaborate with, motivate and influence various levels within the organization, and forge strong relationships with stakeholders outside of the organization.Strong understanding of regulatory and policy landscape related to patient advocacy. Knowledge of marketing, strategic and long-range planning, training, and/or market accessExcellent communication and interpersonal skills, with the ability to collaborate effectively with internal and external stakeholders.Demonstrated ability to lead and inspire cross-functional teams.Passion for improving the lives of patients and caregivers affected by oncology and hematology conditions. Ability to travel up to 30% of the time; domestic and limited international.The base range for an Associate Director is $180,000 - $192,000 and for a Director, it is $221,000 - $233,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.Kura’s Values that are used for candidate selection and performance assessments:We work as one for patientsWe are goal-focused and deliver with excellenceWe are science-driven courageous innovatorsWe strive to bring out the best in each other and ourselvesThe Kura PackageCompetitive comp packageBonus401K + Employer contributionsGenerous stock optionsESPP Plan20 days of PTO to start18 Holidays (Including Summer & Winter Break)Generous Benefits Package with a variety of plans available with a substantial employer matchPaid Paternity/Maternity LeaveIn-Office Catered lunchesHome Office SetupLifestyle Spending StipendCommuter Stipend (Boston Office)Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website atwww.kuraoncology.com and follow us onX andLinkedIn .Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.Accepted file types: pdf, doc, docx, txt, rtfAccepted file types: pdf, doc, docx, txt, rtfWhat is your preferred name? *Where did you hear about this job? * Select...Are you open to considering relocation to Boston? Select...Are you open to considering relocation to San Diego? Select...Will you now or in the future require sponsorship for employment to work in the United States? * Select...Why are you the best candidate for the job?What are your salary expectations?Why do you want to work for Kura Oncology?Why are you looking for a new job?Describe the work environment or culture and its management style in which you have experienced the most success.If you were referred by a Kura employee, please share the name of who referred you.EducationSchool * Select...Degree * Select...Select...Select...Start date yearEnd date month Select...End date yearVoluntary Self-Identification For government reporting purposes, we ask candidates to respond to the below self-identification survey.Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file.As set forth in Kura Oncology’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law.If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows:A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.Select...Voluntary Self-Identification of Disability
Form CC-305Page 1 of 1OMB Control Number 1250-0005Expires 04/30/2026Voluntary Self-Identification of Disability Form CC-305 Page 1 of 1 OMB Control Number 1250-0005 Expires 04/30/2026Why are you being asked to complete this form?We are a federal contractor or subcontractor. The law requires us to provide equal employment opportunity to qualified people with disabilities. We have a goal of having at least 7% of our workers as people with disabilities. The law says we must measure our progress towards this goal. To do this, we must ask applicants and employees if they have a disability or have ever had one. People can become disabled, so we need to ask this question at least every five years.Completing this form is voluntary, and we hope that you will choose to do so. Your answer is confidential. No one who makes hiring decisions will see it. Your decision to complete the form and your answer will not harm you in any way. If you want to learn more about the law or this form, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp .How do you know if you have a disability?
A disability is a condition that substantially limits one or more of your “major life activities.” If you have or have ever had such a condition, you are a person with a disability.
Disabilities include, but are not limited to:Alcohol or other substance use disorder (not currently using drugs illegally)Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, HIV/AIDSBlind or low visionCancer (past or present)Cardiovascular or heart diseaseCeliac diseaseCerebral palsyDeaf or serious difficulty hearingDiabetesDisfigurement, for example, disfigurement caused by burns, wounds, accidents, or congenital disordersEpilepsy or other seizure disorderGastrointestinal disorders, for example, Crohn's Disease, irritable bowel syndromeIntellectual or developmental disabilityMental health conditions, for example, depression, bipolar disorder, anxiety disorder, schizophrenia, PTSDMissing limbs or partially missing limbsMobility impairment, benefiting from the use of a wheelchair, scooter, walker, leg brace(s) and/or other supportsNervous system condition, for example, migraine headaches, Parkinson’s disease, multiple sclerosis (MS)Neurodivergence, for example, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, dyslexia, dyspraxia, other learning disabilitiesPartial or complete paralysis (any cause)Pulmonary or respiratory conditions, for example, tuberculosis, asthma, emphysemaShort stature (dwarfism)Traumatic brain injuryDisability Status Select...
PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.
#J-18808-Ljbffr